Co-Authors
This is a "connection" page, showing publications co-authored by Youhua Xie and Shuai Xia.
Connection Strength
0.636
-
Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. Signal Transduct Target Ther. 2021 07 29; 6(1):288.
Score: 0.240
-
A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. Acta Pharm Sin B. 2021 Aug 02.
Score: 0.060
-
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020 11 27; 5(1):282.
Score: 0.057
-
Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. Proc Natl Acad Sci U S A. 2020 11 03; 117(44):27141-27147.
Score: 0.057
-
Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. JAMA Intern Med. 2020 10 01; 180(10):1356-1362.
Score: 0.057
-
Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. 2020 08; 17(8):894.
Score: 0.056
-
Identification of Human Single-Domain Antibodies against SARS-CoV-2. Cell Host Microbe. 2020 06 10; 27(6):891-898.e5.
Score: 0.055
-
RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. 2020 04 07.
Score: 0.055